Cargando…

Caution in Using the Activated Partial Thromboplastin Time to Monitor Argatroban in COVID-19 and Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT)

INTRODUCTION: Argatroban is licensed for patients with heparin-induced thrombocytopenia and is conventionally monitored by activated partial thromboplastin time (APTT) ratio. The target range is 1.5 to 3.0 times the patients’ baseline APTT and not exceeding 100 s, however this baseline is not always...

Descripción completa

Detalles Bibliográficos
Autores principales: Guy, Susan, Kitchen, Steve, Makris, Michael, M. Maclean, Rhona, Saccullo, Giorgia, Vanveen, Joost J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8689594/
https://www.ncbi.nlm.nih.gov/pubmed/34905962
http://dx.doi.org/10.1177/10760296211066945
_version_ 1784618565088837632
author Guy, Susan
Kitchen, Steve
Makris, Michael
M. Maclean, Rhona
Saccullo, Giorgia
Vanveen, Joost J
author_facet Guy, Susan
Kitchen, Steve
Makris, Michael
M. Maclean, Rhona
Saccullo, Giorgia
Vanveen, Joost J
author_sort Guy, Susan
collection PubMed
description INTRODUCTION: Argatroban is licensed for patients with heparin-induced thrombocytopenia and is conventionally monitored by activated partial thromboplastin time (APTT) ratio. The target range is 1.5 to 3.0 times the patients’ baseline APTT and not exceeding 100 s, however this baseline is not always known. APTT is known to plateau at higher levels of argatroban, and is influenced by coagulopathies, lupus anticoagulant and raised FVIII levels. It has been used as a treatment for COVID-19 and Vaccine-induced Immune Thrombocytopenia and Thrombosis (VITT). Some recent publications have favored the use of anti-IIa methods to determine the plasma drug concentration of argatroban. METHODS: Plasma of 60 samples from 3 COVID-19 patients and 54 samples from 5 VITT patients were tested by APTT ratio and anti-IIa method (dilute thrombin time dTT). Actin FS APTT ratios were derived from the baseline APTT of the patient and the mean normal APTT. RESULTS: Mean APTT ratio derived from baseline was 1.71 (COVID-19), 1.33 (VITT) compared to APTT ratio by mean normal 1.65 (COVID-19), 1.48 (VITT). dTT mean concentration was 0.64 µg/ml (COVID-19) 0.53 µg/ml (VITT) with poor correlations to COVID-19 baseline APTT ratio r(2) = 0.1526 p <0.0001, mean normal r(2) = 0.2188 p < 0.0001; VITT baseline APTT ratio r(2) = 0.04 p < 0.001, VITT mean normal r(2) = 0.0064 p < 0.001. CONCLUSIONS: We believe that dTT is a superior method to monitor the concentration of argatroban, we have demonstrated significant differences between APTT ratios and dTT levels, which could have clinical impact. This is especially so in COVID-19 and VITT.
format Online
Article
Text
id pubmed-8689594
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-86895942021-12-22 Caution in Using the Activated Partial Thromboplastin Time to Monitor Argatroban in COVID-19 and Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT) Guy, Susan Kitchen, Steve Makris, Michael M. Maclean, Rhona Saccullo, Giorgia Vanveen, Joost J Clin Appl Thromb Hemost Original Manuscript INTRODUCTION: Argatroban is licensed for patients with heparin-induced thrombocytopenia and is conventionally monitored by activated partial thromboplastin time (APTT) ratio. The target range is 1.5 to 3.0 times the patients’ baseline APTT and not exceeding 100 s, however this baseline is not always known. APTT is known to plateau at higher levels of argatroban, and is influenced by coagulopathies, lupus anticoagulant and raised FVIII levels. It has been used as a treatment for COVID-19 and Vaccine-induced Immune Thrombocytopenia and Thrombosis (VITT). Some recent publications have favored the use of anti-IIa methods to determine the plasma drug concentration of argatroban. METHODS: Plasma of 60 samples from 3 COVID-19 patients and 54 samples from 5 VITT patients were tested by APTT ratio and anti-IIa method (dilute thrombin time dTT). Actin FS APTT ratios were derived from the baseline APTT of the patient and the mean normal APTT. RESULTS: Mean APTT ratio derived from baseline was 1.71 (COVID-19), 1.33 (VITT) compared to APTT ratio by mean normal 1.65 (COVID-19), 1.48 (VITT). dTT mean concentration was 0.64 µg/ml (COVID-19) 0.53 µg/ml (VITT) with poor correlations to COVID-19 baseline APTT ratio r(2) = 0.1526 p <0.0001, mean normal r(2) = 0.2188 p < 0.0001; VITT baseline APTT ratio r(2) = 0.04 p < 0.001, VITT mean normal r(2) = 0.0064 p < 0.001. CONCLUSIONS: We believe that dTT is a superior method to monitor the concentration of argatroban, we have demonstrated significant differences between APTT ratios and dTT levels, which could have clinical impact. This is especially so in COVID-19 and VITT. SAGE Publications 2021-12-15 /pmc/articles/PMC8689594/ /pubmed/34905962 http://dx.doi.org/10.1177/10760296211066945 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Manuscript
Guy, Susan
Kitchen, Steve
Makris, Michael
M. Maclean, Rhona
Saccullo, Giorgia
Vanveen, Joost J
Caution in Using the Activated Partial Thromboplastin Time to Monitor Argatroban in COVID-19 and Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT)
title Caution in Using the Activated Partial Thromboplastin Time to Monitor Argatroban in COVID-19 and Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT)
title_full Caution in Using the Activated Partial Thromboplastin Time to Monitor Argatroban in COVID-19 and Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT)
title_fullStr Caution in Using the Activated Partial Thromboplastin Time to Monitor Argatroban in COVID-19 and Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT)
title_full_unstemmed Caution in Using the Activated Partial Thromboplastin Time to Monitor Argatroban in COVID-19 and Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT)
title_short Caution in Using the Activated Partial Thromboplastin Time to Monitor Argatroban in COVID-19 and Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT)
title_sort caution in using the activated partial thromboplastin time to monitor argatroban in covid-19 and vaccine-induced immune thrombocytopenia and thrombosis (vitt)
topic Original Manuscript
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8689594/
https://www.ncbi.nlm.nih.gov/pubmed/34905962
http://dx.doi.org/10.1177/10760296211066945
work_keys_str_mv AT guysusan cautioninusingtheactivatedpartialthromboplastintimetomonitorargatrobanincovid19andvaccineinducedimmunethrombocytopeniaandthrombosisvitt
AT kitchensteve cautioninusingtheactivatedpartialthromboplastintimetomonitorargatrobanincovid19andvaccineinducedimmunethrombocytopeniaandthrombosisvitt
AT makrismichael cautioninusingtheactivatedpartialthromboplastintimetomonitorargatrobanincovid19andvaccineinducedimmunethrombocytopeniaandthrombosisvitt
AT mmacleanrhona cautioninusingtheactivatedpartialthromboplastintimetomonitorargatrobanincovid19andvaccineinducedimmunethrombocytopeniaandthrombosisvitt
AT saccullogiorgia cautioninusingtheactivatedpartialthromboplastintimetomonitorargatrobanincovid19andvaccineinducedimmunethrombocytopeniaandthrombosisvitt
AT vanveenjoostj cautioninusingtheactivatedpartialthromboplastintimetomonitorargatrobanincovid19andvaccineinducedimmunethrombocytopeniaandthrombosisvitt